179321-49-4

Basic information

• Product Name: 4-N-Boc-aminocyclohexanone
• Synonyms: BOC-4-AMINOCYCLOHEXANONE;(4-OXO-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER;4-N-BOC-AMINOCYCLOHEXANONE;4-N-BOC-4-AMINOCYCLOHEXANONE;4-AMINOCYCLOHEXANONE N-BOC PROTECTED;N-4-BOC-AMINOCYCLOHEXANONE;N-T-BOC-4-AMINOCYCLOHEXANONE;TERT-BUTYL 4-OXOCYCLOHEXYLCARBAMATE
• CAS NO: 179321-49-4
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27
• EINECS: 1806241-263-5
• Product Categories: N-BOC;Amines;blocks;Acids and Derivatives;Carbonyl Compounds;pharmacetical;CHIRAL CHEMICALS;Building Blocks;C10 to C11;C11 to C12;Chemical Synthesis;Ethers;New Products for Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks;Oxygen Compounds
• Mol File: 179321-49-4.mol

Chemical Properties

• Melting Point: 114-118℃
• Boiling Point: 335.9 °C at 760 mmHg
• Flash Point: 157 °C
• Appearance: /
• Density: 1.06 g/cm³
• Vapor Pressure: 0.000116mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• PKA: 12.19±0.20(Predicted)
• CAS DataBase Reference: 4-N-Boc-aminocyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-Boc-aminocyclohexanone(179321-49-4)
• EPA Substance Registry System: 4-N-Boc-aminocyclohexanone(179321-49-4)

Safety Data

• Hazard Codes: Xi,N
• Statements: 36/37/38-50
• Safety Statements: 26-36/37/39-61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 179321-49-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-N-Boc-aminocyclohexanone is used as an intermediate in the synthesis of various pharmaceuticals for its ability to facilitate selective modification of the molecule. The Boc protecting group allows chemists to carry out reactions on other parts of the molecule without affecting the amino group, which is crucial for the development of specific drug candidates.
Used in Organic Chemistry:
In the field of organic chemistry, 4-N-Boc-aminocyclohexanone is employed as a valuable intermediate in the synthesis of a range of organic compounds. Its unique structure and the Boc protecting group make it an essential component in the creation of complex organic molecules with potential applications in various industries.
Used in Bioactive Compound Synthesis:
4-N-Boc-aminocyclohexanone is used as a key intermediate in the synthesis of bioactive compounds, contributing to the development of new therapeutic agents and other biologically relevant molecules. Its role in the synthesis of these compounds highlights its importance in advancing the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C11H19NO3/c1-11(2,3)15-10(14)12-8-4-6-9(13)7-5-8/h8H,4-7H2,1-3H3,(H,12,14)

Upstream product

• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 224309-64-2 tert-butyl N-(4-hydroxycyclohexyl)carbamate 
• 79-37-8 oxalyl dichloride 
• 114615-82-6 tetrapropylammonium perruthennate 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 7529-22-8 4-methylmorpholine N-oxide 
• 6850-65-3 p-hydroxycyclohexylamine 
• 87413-09-0 Dess-Martin periodane 
• 87976-86-1 4‐aminocyclohexanone 
• 34619-03-9 tert-butyldicarbonate 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 

Downstream Products

• 503817-60-5 3-(4-t-butoxycarbonylaminocyclohexylidene)-1-tetrahydropyranyloxypropane 
• 725255-70-9 tert-butyl (4-methylenecyclohexyl)carbamate 
• 868528-95-4 4-(N,N-bis(tert-butoxycarbonyl)amino)cyclohexanone 
• 886206-08-2 {4-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 1001414-20-5 tert-butyl N-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)cyclohex-3-en-1-yl]carbamate 
• 1013921-23-7 C₂HF₃O₂*C₆H₁₁NO 
• 1171130-67-8 (3-dimethylaminomethylene-4-oxo-cyclohexyl)-carbamic acid tert-butyl ester 
• 910605-31-1 {4-[4-(2-cyclopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 910605-45-7 (4-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperidin-1-yl}-cyclohexyl)-carbamic acid tert-butyl ester 
• 946605-78-3 C₂₄H₃₇FN₂O₃ 
• 946605-79-4 C₂₄H₃₆F₂N₂O₃ 
• 910605-67-3 {4-[4-(4-fluoro-2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 946605-80-7 C₂₅H₃₉FN₂O₃ 
• 886206-13-9 C₂₃H₃₄F₃N₃O₃ 

Relevant articles and documents

FeCl3·6H2O/acetaldehyde, a versatile system for the deprotection of ketals and acetals via a transacetalization process

Mild and efficient catalytic deprotection of ketals/acetals mediated by FeCl3·6H2O/acetaldehyde has been described in this paper. The versatility and high chemoselectivity of the iron(iii)/aldehyde system are demonstrated by a large scope of examples. Deprotected ketones/aldehydes are nearly quantitatively isolated after filtration over a pad of silica gel followed by evaporation of volatile by-products.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

Iridinesulfonamide compound and use method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a pro

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Highly chemoselective aerobic oxidation of amino alcohols into amino carbonyl compounds

The direct oxidation of unprotected amino alcohols to their corresponding amino carbonyl compounds has often posed serious challenges in organic synthesis and has constrained chemists to adopting an indirect route, such as a protection/deprotection strategy, to attain their goal. Described herein is a highly chemoselective aerobic oxidation of unprotected amino alcohols to their amino carbonyl compounds in which 2-azaadamantane N-oxyl (AZADO)/copper catalysis is used. The catalytic system developed leads to the alcohol-selective oxidation of various unprotected amino alcohols, carrying a primary, secondary, or tertiary amino group, in good to high yield at ambient temperature with exposure to air, thus offering flexibility in the synthesis of nitrogen-containing compounds. Strong as an ox: The highly chemoselective aerobic oxidation of unprotected amino alcohols to their corresponding amino carbonyl compounds has been achieved by using 2-azaadamantane N-oxyl (AZADO)/copper catalysis. This catalytic system oxidizes not only alcohols with tertiary amino groups but also those with secondary and primary amines in good to high yield at ambient temperature in air. bpy=2,2-bipyridyl, DMAP=4-(N,N-dimethylamino)pyridine.

Synthesis and structure-activity relationship studies on novel 8-amino-3-[2-(4-fluorophenoxy)ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione derivatives as anticonvulsant agents

A series of novel 8-amino-3-[2-(4-fluorophenoxy)ethyl]-1,3-diazaspiro[4.5] decane-2,4-dione derivatives 7-36 was synthesized and their pharmacological activity was determined with the objective to better understand their structure-activity relationship for anticonvulsant activity. All the compounds were evaluated for their possible anticonvulsant activity by maximal electroshock seizure (MES) test and their neurotoxic effects were determined by rotarod test. Majority of the compounds were active in MES tests. Compounds 24, 27, and 34 showed a significant and protective effect on seizure, when compared with standard drug phenytoin. The compounds having amide bond showed moderate protective effect on MES induced seizures compared to sulfonamide.